Curated News
By: NewsRamp Editorial Staff
February 20, 2026

MangoRx's $99 TRT Program Sees 336% Sales Surge, Cuts Acquisition Costs

Discuss on Substack
Original Source

TLDR

  • Mangoceuticals' $99 monthly TRT program offers a cost-effective advantage in the $2.2 billion hormone therapy market with 336% sales growth and 54% lower acquisition costs.
  • MangoRx's all-inclusive TRT program works via telehealth: doctor visits, consultations, lab work, and medication are bundled for $99 monthly and shipped discreetly to patients.
  • MangoRx's affordable telehealth TRT program improves men's health access, making hormone therapy more convenient and discreet for better quality of life worldwide.
  • MangoRx's TRT sales surged 336% in a month, showing explosive demand for its $99 all-inclusive hormone therapy via telehealth in a growing global market.

Impact - Why it Matters

This development matters because it represents a significant shift in healthcare accessibility and affordability, particularly for men's wellness. Testosterone replacement therapy, often a costly and inconvenient process involving multiple clinic visits, is now being offered as a streamlined, all-inclusive monthly subscription via telehealth. The program's rapid sales growth and reduced customer acquisition costs suggest it is effectively meeting a substantial, underserved market demand. For consumers, this means easier, more private, and potentially more affordable access to a treatment that can significantly impact quality of life, energy levels, and overall health. For the healthcare and investment sectors, it demonstrates the viability and scalability of subscription-based, direct-to-consumer telehealth models for managing chronic conditions, potentially paving the way for similar innovations in other specialty medication areas. The success also highlights Mangoceuticals' strategic positioning to capture a share of the multi-billion dollar global TRT market.

Summary

Mangoceuticals, Inc., operating under its MangoRx and PeachesRx brands, has announced remarkable initial success for its newly launched all-inclusive injectable testosterone replacement therapy (TRT) program, priced at an accessible $99 per month. This comprehensive program includes doctor visits, consultations, lab work, and prescribed medication, delivered through the company's secure telemedicine platform. Since its mid-December launch, the program has seen a staggering 336% month-over-month sales increase, while customer acquisition costs have simultaneously declined by 54%, indicating strong market traction and efficient growth. The company, which trades on the NASDAQ under the symbol MGRX, views this TRT offering as a primary growth driver as it seeks to expand its presence in the global TRT market, estimated to reach approximately $2.1 to $2.2 billion by 2025. The program's success underscores a growing consumer demand for convenient, integrated hormone health solutions.

MangoRx is a company focused on developing men's health and wellness products and services, currently offering treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management via its telemedicine platform. The process allows interested consumers to have prescription requests reviewed by a licensed medical provider, with approved medications discreetly shipped directly to their doorstep through a partner compounding pharmacy. This announcement was distributed by MissionIR (MIR), a specialized communications platform within the Dynamic Brand Portfolio of IBN (InvestorBrandNetwork). MissionIR provides services like access to wire solutions via InvestorWire, article syndication to over 5,000 outlets, and enhanced press release distribution to help companies like Mangoceuticals gain visibility within the investment community and beyond.

For more detailed information, readers can view the full press release. To learn more about MangoRx's broader mission and its full suite of products, including oral formulations like PRIME by MangoRx powered by Kyzatrex, interested parties are encouraged to visit the company's official website. The news highlights how telehealth platforms are revolutionizing access to specialized medical treatments, making comprehensive care like hormone replacement therapy more affordable and convenient than traditional in-person clinic models, which often involve higher costs and more logistical hurdles for patients.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, MangoRx's $99 TRT Program Sees 336% Sales Surge, Cuts Acquisition Costs

blockchain registration record for this content.